18738-58-4

Basic information

• Product Name: 4-(4-METHOXY-PHENYLSULFAMOYL)-BENZOIC ACID
• Synonyms: Benzoicacid, p-[(p-methoxyphenyl)sulfamoyl]- (8CI); N-(4-Methoxyphenyl)4-carboxybenzenesulfonamide
• CAS NO: 18738-58-4
• Molecular Formula: C₁₄H₁₃NO₅S
• Molecular Weight: 0
• Mol File: 18738-58-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 515.6°Cat760mmHg
• Flash Point: 265.6°C
• Appearance: /
• Density: 1.428g/cm³
• Vapor Pressure: 1.87E-11mmHg at 25°C
• CAS DataBase Reference: 4-(4-METHOXY-PHENYLSULFAMOYL)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHOXY-PHENYLSULFAMOYL)-BENZOIC ACID(18738-58-4)
• EPA Substance Registry System: 4-(4-METHOXY-PHENYLSULFAMOYL)-BENZOIC ACID(18738-58-4)

Safety Data

• Hazardous Substances Data: 18738-58-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H13NO5S/c1-20-12-6-4-11(5-7-12)15-21(18,19)13-8-2-10(3-9-13)14(16)17/h2-9,15H,1H3,(H,16,17)/p-1

Upstream product

• 10130-89-9 p-carboxyphenylsulfonyl chloride 
• 104-94-9 4-methoxy-aniline 
• 1119833-21-4 methyl 4-(N-(4-methoxyphenyl)sulfamoyl)benzoate 
• 69812-51-7 4-chlorosulfonyl-benzoic acid methyl ester 

Relevant articles and documents

Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis

A series of thiophene-benzenesulfonamide derivatives was designed and synthesized by exploring the structure-activity relationship of lead compounds 2,3-disubstituted thiophenes 25a and 297F as antituberculosis agents, which displayed potent antimycobacterial activity against drug-susceptible and clinically isolated drug-resistant tuberculosis. In particular, compound 17b, which had improved activity (minimum inhibitory concentration of 0.023 μg/mL) compared with the lead compounds, displayed good intracellular antimycobacterial activity in macrophages with a reduction of 1.29 log10 CFU. A druggability evaluation indicated that compound 17b had favorable hepatocyte stability, low cytotoxicity, and low hERG channel inhibition. Moreover, compound 17b exhibited modest in vivo efficacy in an acute mouse model of tuberculosis. In addition, the molecular docking study elucidated the binding mode of compound 17b in the active site of DprE1. Therefore, compound 17b may be a promising antituberculosis lead for further research.

Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors

In order to create novel analgesic agents without gastric disturbance, structurally simple cyclooxygenase-1 (COX-1) inhibitors with a benzenesulfonanilide skeleton were designed and synthesized. As a result, compounds 11f and 15a, which possess a p-amino group on the benzenesulfonyl moiety and p-chloro group on the anilino moiety, showed COX-1-selective inhibition. Moreover compound 11f, which is the most potent compound in this study showed more potent analgesic activity than that of aspirin at 30 mg/kg by po. The anti-inflammatory activity and gastric damage, however, were very weak or not detectably different from aspirin. Since the structure of our COX-1 inhibitors are very simple, they may be useful as lead compounds for superior COX-1 inhibitors as analgesic agents without gastric disturbance.